QA: Y mAbs Therapeutics Inc in us_pharma/2022

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0001722964_2023_Y_mAbs_Therapeutics_Inc.pdf

Logs

warning The stock price does not exist industry.us_generic {}

Graph

Absolute values for 0001722964, Y mAbs Therapeutics Inc

  xvar xval
0 AssetsCurrent 130,447,000
1 IntangibleAssetsNetIncludingGoodwill 2,986,000
2 PropertyPlantAndEquipmentNet 604,000
3 remainder_Assets 7,419,000
4 LiabilitiesCurrent 28,284,000
5 LiabilitiesNoncurrent 1,701,000
6 remainder_Liabilities 2,250,000
7 CostOfGoodsAndServicesSold 33,265,532
8 SellingGeneralAndAdministrativeExpense 74,337,318
9 ResearchAndDevelopmentExpense 88,950,520
10 remainder_Expenses 136,138
11 remainder_Revenues 216,700,181
12 remainder_NetIncome 59,732,603
13 remainder_ComprehensiveNetIncome 1,665,351
  yvar yval
0 Assets 141,456,000
1 Liabilities 32,235,000
2 Expenses 196,689,508
3 Revenues 216,700,181
4 StockholdersEquity 109,221,000
5 NetIncome 79,743,276
6 ComprehensiveNetIncome 80,575,952
7 BaseVar 324,239,322
8 EconomicCapitalRatiobeforeLimitedLiability 3.67
9 EconomicCapitalRatio 4.15

Edgar->Model Mapping

Feature Distribution

Change over Time